SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Restructurings
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
From: tuck2/22/2018 10:11:39 AM
   of 270
 
Achillion (ACHN) 20% in aftermath of Hep C program termination. Widely expected, and the stock isn't reacting much. Now a complement factor D company with a fair amount of cash, but of course their programs are early, if promising. I have a position, and have it as a charity pick.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News